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Eirik Skogvoll1* and Jo Kramer-Johansen2Scandinavian Journal of Trauma, Resuscitation and
Emergency Medicine (SJTREM) receives about 220
submissions for publication every year. Based on the
principles of open access publishing, all scientifically
sound manuscript that are original and in compliance
with ethical and author guidelines will be considered for
publication. Such editorial policies are in effect in most
journals, and together with rigorous peer-review they are
the cornerstones of scientific dissemination. The rejec-
tion rates for submitted papers and the citations to
published papers are considered when overall quality or
impact of a journal is evaluated; however, both these
metrics have serious shortcomings and can’t be used for
comparison between journals without caution. SJTREM
currently rejects 60% of all submitted papers; the current
impact factor is 1.85.
In clinical medicine we want to provide our patients with
the best possible treatment, and we need to know whether
some new intervention is more effective than what we have
been used to doing. To find out, we need clinical trials.
The crucial point in any comparison is to be fair, and in
scientific terms this means to rule out as many sources of
bias and confounding as possible. Randomization is a
powerful tool to ensure that unknown factors will be
evenly distributed among the experimental groups, and the
randomized controlled trial (RCT) is the golden standard.
But even the most elegant study could end up unpublished
if the results are unexpected (or even unwanted!), or the
results may be tweaked to satisfy a study sponsor’s financial
interests. Fear of such publication bias led to registries of
clinical trials. Registration has become required for publi-
cation in most medical journals [1], and also regulated
by laws in some countries. The purpose of such registra-
tion is mainly to have publicly disclosure of the ethical
considerations, intentions and rationale before recruiting
subjects into the trial, and secondarily it will help avoid* Correspondence: eirik.skogvoll@ntnu.no
1Department of Anaesthesia and Intensive Care, St. Olav University Hospital,
Trondheim, Norway
Full list of author information is available at the end of the article
© 2013 Skogvoll and Kramer-Johansen; license
of the Creative Commons Attribution License
distribution, and reproduction in any mediumplanning and funding studies that already are running;
finally it may serve as a data repository after the end of
the study to provide other researchers opportunity to
verify or collate results. For journals that must decide on
publication, these registries provide opportunity to verify
that the submitted paper adheres to the original plan for
conduct and analysis. Even so, a recent analysis of 40 RCTs
published after 2005 revealed improper presentation of
outcomes or analyses in up to 75% of the studies when
compared with the original protocol, and late registration
into ClinicalTrials.gov in a similar proportion (url: http://
www.ncbi.nlm.nih.gov/books/NBK100613/, accessed January
18, 2013).
The reasons mentioned above give sound reason to
publish or make publicly available full protocols of clin-
ical trials. For the editors, the question remains whether
the protocol represents a redundant publication when it
is already publicly available in registries. For the com-
petitive researcher, the question may be how to get
properly rewarded for the huge amount of work that has
been put into protocol development, in a system where
counting of publications may define your further funding
or promotions. An additional issue of grievance for the
publisher may be that even if agreeing to publish the
protocol, there may be small chances to receive the final
results for publication due to an understandable quest
for high-impact journals and prestigious papers.
Sten Rubertsson and colleagues here present their
protocol from the LINC study, which just finished inclu-
sion of patients. The LINC study is a randomized con-
trolled trial of mechanical chest compressions with
LUCAS™ combined with a specific algorithm of chest
compressions and defibrillations.
After careful editorial consideration, SJTREM has
decided to publish the protocol even if the research and
analysis plan have been publicly available on ClinicalTrials.
gov since 2008 (NTC 00609778). The published protocol
provides additional rationale and background for the trial,
as well as a detailed description of the organization of the
trial; hopefully it may aid others to organize a clinical trial.e BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for peer-review to change besides issues of language and
clarity. We will therefore print the original protocol more
or less as submitted and instead provide a critical com-
mentary of the protocol in this editorial. The authors have
the opportunity to respond separately.
As an aid in this process, we will follow the 10-
dimensional Trial Quality assessment list suggested by
Berger and Alperson [2]. This paper aims at identifying
unique aspects that may influence trial quality, and differs
from previous systems for trial assessment by proposing
that the final “quality score” should be obtained by multi-
plying individual scores. We have avoided the scoring,
though, and apply the list in only in a “check-list” or quali-
tative way. We will also briefly comment on what was
made public on ClinicalTrials.gov, and finally on what we
perceive as strengths and weaknesses of the study.
LINC trial quality
Randomization
Patients were randomized individually as soon as possible
after the decision to treat was made, by opening an enve-
lope containing instructions of whether to use or not use
LUCAS. The inclusion criteria are wide, but it is unclear
whether the arrest needs to be “witnessed by sight or
sound”, as the contrary appears to be a protocol violation.
It is not reported neither by what means the randomization
table was generated, nor whether the envelopes were
tracked (for example by numbering). The latter is neces-
sary for an intention-to-treat analysis and to detect proto-
col violations. It has been revealed [Sten Rubertsson,
personal communications, Resuscitation 2012, Vienna,
Austria] that during the early phase of the study ambu-
lance staff were able to foresee the next allocation by
carefully inspecting the (slightly transparent) envelopes,
necessitating a change to black, opaque envelopes.
While the ability to foresee the next treatment alloca-
tion may lead to inclusion bias in either direction, the
extent is unknown.
To maintain a balance between the study groups at
each site, block randomization is a common method.
The LINC study employed stratified randomization by
EMS site (or perhaps by ambulance station, or even indi-
vidual ambulances ?) in blocks of six, meaning that each
site is guaranteed to have a balanced number of patients
in the two arms for each six patient recruited. The block
size has allegedly been kept secret to reduce the possibility
of knowing the next allocation after five patients have
been included. Apparently, however, this has been known
to the group of authors.
Masking
The study is single blinded. By nature of the intervention
the allocation is known to the ambulance personnel.Allocation concealment
See point 2. It is not described in the protocol whether
(or how) treatment allocation is concealed for the
personnel who registered the outcome.
Withdrawals and dropouts
By nature of the study, informed consent cannot be
obtained before inclusion. Surviving patients (or next-of-kin
acting on their behalf) may withdraw from the study,
and they will not be included in what is denoted as the
Intention to treat (ITT) population. This may bias the
analysis– which by definition is no longer by ITT– but
because one does not know which treatment is better it is
hard to guess the direction.
Baseline data
The presenting rhythm has not been recorded, but
guessed. It is well known that patients presenting with
ventricular fibrillation or ventricular tachycardia (VF/
VT) have a better prognosis than patients with pulseless
electrical activity (PEA) or asystole (ASY). The chosen
design thus precludes inference regarding any differen-
tial effects of LUCAS according to presenting rhythm.
Endpoints
The primary endpoint is 4-hour survival, a surrogate
measure. This particular choice is not substantiated.
Being alive at 4 hours is an obvious prerequisite for the
ultimate goal, which is hospital discharge without severe
neurological impairment. The intervention may have be-
come known to the treating physician after admission
(see points 2 and 3 above) and 4 hours is not a very long
time. It is therefore possible that the decision to with-
draw or continue further treatment (e.g. proceed to PCI,
induce hypothermia etc.) may have been influenced by
knowledge of the experimental intervention. The pri-
mary outcome is thus not very robust because of the
single-blind nature of the trial.
Stopping rules
The study was continued after an interim analysis after
recruitment of 1500 patients was carried out during
spring 2011 by an independent safety committee. Pre-
sumably, the strict criterion of p < 0.005 – that either
treatment much better than the other – was not met,
while a meaningful difference might still be detected.
Statistical methods
The planned group comparison is via Fishers exact test.
It is not reported whether site will be included as ran-
dom effects, although this may be expected due to the
stratified randomization scheme (point 1). The sample
size (total 2500 patients) has been calculated assuming a
6% difference for the primary surrogate outcome.
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Confidence intervals for difference in proportions will be
reported. If a random effects model (site) is employed as
expected, the variance components as well as intraclass
correlation should be reported.
Multiple testing and adjusting the p-values
Not mentioned.
What was reported on clinicaltrials.gov?
The website was accessed on 9.th October 2012. With iden-
tifier NCT 00609778, the trial was registered first in January
2008 and lastly updated in October 2012. Inclusion was
completed in August 2012. Although details are lacking,
the presentation is consistent with the present protocol.
Major strengths and weaknesses of the study
The study has major strengths and the authors should
be commended for planning and carrying out relevant
clinical research under emergency circumstances. A pro-
spective randomized design is the best way to assess an
intervention. The large sample size furthermore allows
for detection of a realistic outcome improvement. To re-
cruit the necessary number of patients, national and
international collaboration allows for study completion
within a realistic time frame. Finally, all patients will be
accounted for.
There is however a number of weaknesses with this
study; mainly related to generalizability and the potential
for bias. As for the ability to generalize the results, the
device under investigation is confounded with the CPR
algorithm. This precludes inference about the effect of
LUCAS itself, so the question of whether mechanic
compressions are better than manual compressions dur-
ing CPR will remain unanswered. Furthermore, the ini-
tial rhythm is not recorded, so it is not possible to know
whether there is any differential effect here. Regarding
potential bias, inclusion into the study may have been
influenced by ambulance staff knowing the next alloca-
tion (point 1, above). Then the primary outcome may be
influenced by knowledge of the intervention (point 6,
above). Finally, the proposed analyses are not really by
ITT due to the potential effect of selective patient with-
drawal (point 4, above).
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